172 related articles for article (PubMed ID: 12880966)
1. The p53 pathway and its inactivation in neuroblastoma.
Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
[TBL] [Abstract][Full Text] [Related]
2. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA; Malcolm AJ; Cole M; Pearson AD; Lunec J
Am J Pathol; 2001 Jun; 158(6):2067-77. PubMed ID: 11395384
[TBL] [Abstract][Full Text] [Related]
3. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
4. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
[TBL] [Abstract][Full Text] [Related]
5. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
6. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
[TBL] [Abstract][Full Text] [Related]
9. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
11. p53 is a direct transcriptional target of MYCN in neuroblastoma.
Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
Carr J; Bell E; Pearson AD; Kees UR; Beris H; Lunec J; Tweddle DA
Cancer Res; 2006 Feb; 66(4):2138-45. PubMed ID: 16489014
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.
Tweddle DA; Malcolm AJ; Bown N; Pearson AD; Lunec J
Cancer Res; 2001 Jan; 61(1):8-13. PubMed ID: 11196202
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
16. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
Rodriguez-Lopez AM; Xenaki D; Eden TO; Hickman JA; Chresta CM
Mol Pharmacol; 2001 Jan; 59(1):135-43. PubMed ID: 11125034
[TBL] [Abstract][Full Text] [Related]
17. The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
Mazar J; Rosado A; Shelley J; Marchica J; Westmoreland TJ
Oncotarget; 2017 Jan; 8(4):6589-6607. PubMed ID: 28035057
[TBL] [Abstract][Full Text] [Related]
18. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP; Bekkum MV; Chen B; Tan O; Ellis T; Norris MD; Haber M; Kim ES; Shohet JM; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM
Oncogene; 2013 Aug; 32(31):3616-26. PubMed ID: 22907436
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
20. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
Carr-Wilkinson J; O'Toole K; Wood KM; Challen CC; Baker AG; Board JR; Evans L; Cole M; Cheung NK; Boos J; Köhler G; Leuschner I; Pearson AD; Lunec J; Tweddle DA
Clin Cancer Res; 2010 Feb; 16(4):1108-18. PubMed ID: 20145180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]